Cataya, a synthetic biology company focused on biomanufacturing of chemical and biochemical products, has raised over 100 million yuan in Series A+ funding,  co-led by Eight Roads and Sequoia China. F-Prime Capital, Source Code, and Bits x Bites also participated in this round.

The proceeds will be used for pipeline research and development, talent recruitment, and manufacturing facilities construction. The company has completed three rounds of financing within just one year, which demonstrates its fast development and great market potential. It will also set up its research and business units in the US and Japan in the future.

Founded in 2021, Cataya’s pipeline consists of high-value, targeted ingredient molecules with broad applications in food, cosmetics, and general consumer goods end-products. The company is led by the industry’s most experienced veterans, who have both product development expertise and “go-to-market” commercialization experience. Dr. Lishan Zhao, founder and CEO of Cataya, is one of the most recognized leaders in the biomanufacturing industry globally.

Betty Cai, Partner of Eight Roads Ventures China, and Chersy Miao, Principle of Eight Roads Ventures China remarked: "We are pleased to co-led Cataya’s Series A+ financing round and support Dr. Zhao and his world-class team to realize their vision step by step. The investment is a joint effort of our technology and healthcare team that ensures we provide sufficient resources and support to the company. We are very excited about Cataya’s high quality and multi-layer pipelines, and product-driven R&D platforms, as well as the promising future of China’s biomanufacturing industry.”